RESEARCH TRIANGLE PARK, N.C., Dec. 03, 2025 (GLOBE NEWSWIRE) — BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that it has received early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the “HSR Act”), with respect to BioCryst’s proposed acquisition of Astria Therapeutics, Inc. (the “Merger”). Termination of the waiting period under the HSR Act satisfied one of the conditions for consummation of the Merger. BioCryst expects the Merger to close in the first quarter of 2026, subject to other customary closing conditions. About BioCryst PharmaceuticalsBioCryst is a global biotechnology company focused on developing and commercializing medicines for hereditary angioedema (“HAE”) and other rare diseases, driven by its deep commitment to improving the lives of...

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1.        KEY INFORMATION(a)   Full name of discloser: CANACCORD GENUITY WEALTH LIMITED (for Discretionary clients)(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):        The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c)   Name of offeror/offeree in relation to whose relevant securities this form relates:        Use a separate form for each offeror/offeree IDOX PLC(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: IDOX PLC AS AN ASSOCIATE OF THE CANACCORD...

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1.        KEY INFORMATION(a)   Full name of discloser: CANACCORD GENUITY ASSET MANAGEMENT LIMITED (for Discretionary clients)(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):        The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c)   Name of offeror/offeree in relation to whose relevant securities this form relates:        Use a separate form for each offeror/offeree IQE PLC(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A(e)   Date position held/dealing...

The addition of the leading accessibility technology for communication design expands Quadient’s capabilities for accessible, compliant, and inclusive customer communications Quadient (Euronext Paris: QDT), a global automation platform powering secure and sustainable business connections, today announced the signing of an agreement to acquire CDP Communications, a long-standing Quadient partner and one of the most innovative companies in document accessibility and automation. This acquisition reinforces Quadient’s commitment to inclusion and accessibility in customer communications and marks a significant step toward achieving the company’s Elevate to 2030 strategic objectives. More recently, compliance drivers around accessibility, in Europe and North America in particular, are requiring companies to make all digital content – including...

Acquisition highlights ETİ Gıda’s global expansion strategy and positions TRUBAR for accelerated growth in the better-for-you snacks category.TRUBAR: the plant-based protein bars VANCOUVER, British Columbia, Dec. 02, 2025 (GLOBE NEWSWIRE) — According to CPG Insider, TRUBAR, a better-for-you bar brand under Simply Better Brands (TSE: TRBR), was announced last week to be acquired by ETİ Gıda in a $201 million (CAD) all-cash transaction. The deal, representing a 64% premium over TRUBAR’s previous closing share price, is expected to accelerate the brand’s growth across North America while expanding its global presence. The acquisition has reportedly been recommended by TRUBAR’s Board of Directors and Special Committee, which deemed the partnership in the company’s best interest. ETİ Gıda’s experience in scaling international consumer...

Hyperliquid Strategies Common Stock Expected to Begin Trading on Nasdaq on Wednesday, December 3 Under the Ticker “PURR” NEW YORK and PRINCETON, N.J., Dec. 02, 2025 (GLOBE NEWSWIRE) — Hyperliquid Strategies Inc (“HSI” or the “Company”) and Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN) (“Sonnet”) today announced the completion of the closing of the previously announced business combination among HSI, Sonnet and Rorschach I LLC (“Rorschach”), a newly-formed entity formed by an entity affiliated with Atlas Merchant Capital LLC (“Atlas”), an affiliate of Paradigm Operations LP (“Paradigm”), and additional sponsors (all together, the “Sponsors”), which was approved by Sonnet’s stockholders on December 2, 2025. As a result of the closing, the Company will operate as a HYPE digital asset treasury reserve company, and Sonnet will...

New Partnership Brings Shared Values, Quality Service, and Community CommitmentVictory Tire & AutoVictory Tire & AutoROCHESTER, MN – [December 2, 2025], Dec. 02, 2025 (GLOBE NEWSWIRE) — Victory Tire & Auto, a trusted Minnesota name in complete auto repair since 1997, has announced the acquisition of Babcock Auto Care in Rochester, MN, marking its 24th shop in the state. Jeremy Babcock is a veteran of the automotive industry with over 30 years of experience. Jeremy and his wife, Jeanna Babcock, opened their first shop in Rochester in 2002 and have since grown a group of longstanding, loyal customers whom they proudly serve. Babcock Auto Care has earned its reputation for integrity, skilled service, and deep community ties, which is something Victory Tire & Auto also prides itself on. “From our...

ST. PETERSBURG, FL. – [December 2, 2026], Dec. 02, 2025 (GLOBE NEWSWIRE) — All County Tire & Auto, a trusted name in automotive repair across Florida, is proud to announce the acquisition of JC Automotive in St. Petersburg, Florida. The acquisition marks an exciting step in All County’s continued growth and commitment to providing high-quality automotive care throughout the region. Founded in 1988 by John Celona, JC Automotive has earned a strong reputation for its honesty, reliability, and dedication to customer satisfaction. “The most difficult decision in life is knowing the right time to sell your business,” said John Celona, founder of JC Automotive. “What mattered most to me was ensuring the employees who helped build this company over the years would continue to be valued and supported. When the opportunity came...

EXOUSIA AI SECURES HIGH-VALUE ORPHAN DRUG DESIGNATION ORLANDO, Fla., Dec. 02, 2025 (GLOBE NEWSWIRE) — LAMY, to become Exousia Bio, Inc. (OTCPINK: LMMY) (the “Company” or “Exo Bio”), operating as a leading U.S. biotechnology company focused on exosome-based cancer therapy, today announced the completion of the acquisition of 100% of Exousia AI, Inc. in an all-stock transaction. LAMY issued 62,223,000 restricted shares of its Common stock to finalize the deal, consolidating ownership of a highly promising preclinical oncology platform. Foundation Built on Exclusive, Worldwide Licensing The strategic acquisition reinforces Exousia Bio’s position as an innovator in the exosome space. The Company has secured two exclusive worldwide licenses for Exosome technology. These patented and patent-pending intellectual property rights...

EXOUSIA AI SECURES HIGH-VALUE ORPHAN DRUG DESIGNATION ORLANDO, Fla., Dec. 02, 2025 (GLOBE NEWSWIRE) — LAMY, to become Exousia Bio, Inc. (OTCPINK: LMMY) (the “Company” or “Exo Bio”), operating as a leading U.S. biotechnology company focused on exosome-based cancer therapy, today announced the completion of the acquisition of 100% of Exousia AI, Inc. in an all-stock transaction. LAMY issued 62,223,000 restricted shares of its Common stock to finalize the deal, consolidating ownership of a highly promising preclinical oncology platform. Foundation Built on Exclusive, Worldwide Licensing The strategic acquisition reinforces Exousia Bio’s position as an innovator in the exosome space. The Company has secured two exclusive worldwide licenses for Exosome technology. These patented and patent-pending intellectual property rights...